SCHEMBL6655403

SCHEMBL6655403

CCOc1cc(C2=NN(Cc3ccc(NC(=O)CN4CCN(C)CC4)cc3)C(=O)CC2)ccc1OC

nearest known ligand 0.55

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 3/20 0.55
PDE4B Q07343 9/20 0.54
PDE4A P27815 1/20 0.54
PDE4C Q08493 1/20 0.54
PDE3B Q13370 1/20 0.54
PDE3A Q14432 1/20 0.54
ALDH1A1 P00352 4/20 0.47
ALOX15 P16050 1/20 0.47
LMNA P02545 1/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6655157 0.94 PDE4D (0.56) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL6659073 0.93 PDE4D (0.56) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL6655795 0.92 PDE4D (0.68) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL6659800 0.92 PDE4D (0.54) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL6662782 0.92 PDE4D (0.54) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL6655113 0.91 PDE4D (0.53) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL145391 0.89 PDE4B (0.61) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL6841704 0.88 PDE4D (0.48) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL6657192 0.88 PDE4D (0.52) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL6655995 0.88 PDE4D (0.63) PDE4DPDE4BPDE4APDE4CPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US claimed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 EP claimed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 WO claimed
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 EP disclosed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B PDE4D 12/4885PDE4B 4/4885PDE4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.